ENGLEWOOD, Colo., Nov. 28, 2017 /PRNewswire/ -- Aytu BioScience,
Inc. (NASDAQ: AYTU), a specialty life sciences company focused on
global commercialization of novel products in the field of urology,
today provided an update on the launch of Natesto in the U.S.
Significant Natesto prescription growth continued through
October 2017, with prescriptions
increasing 17% from the previous month, reaching their highest
levels to date. Additionally, in October, the number of
physicians prescribing Natesto increased 16% from the previous
month.
The Company reports the following prescription and prescriber
growth for the one-month and three-month periods ending
October 31, 2017:
- Natesto total prescriptions for the month of October were 827,
representing a 17% increase over September total prescriptions. New
prescriptions for Natesto for the month of October increased to
495.
- The number of prescribers of Natesto for the month of October
was 407, representing a 16% increase over September. New
prescribers represented over 25% of total prescribers in
October.
- Natesto total prescriptions were 2,263 for the three-month
period ending October 2017,
representing a 35% increase over the three-month period ending
July 2017.
Josh Disbrow, Chief Executive
Officer of Aytu BioScience commented, "Aytu is continuing to drive
adoption of Natesto at an accelerated rate, and the Company is
pleased with the ongoing positive reception by physicians and
patients. The combination of a highly differentiated product
profile and our sales force becoming increasingly proficient has
resulted in all-time highs for Natesto in terms of both
prescription levels and prescribers. We remain enthusiastic about
the uptake of Natesto, particularly the large increase over these
past three months, and we are on track to achieve cashflow
breakeven in the quarters ahead based on our forecasted
growth."
The Company expects to continue to provide periodic updates on
the ongoing launch of Natesto in the U.S.
About Aytu BioScience, Inc.
Aytu BioScience is a commercial-stage specialty life sciences
company focused on global commercialization of novel products in
the field of urology, with a focus on products addressing vitality,
sexual wellness, and reproductive health. The Company currently
markets two prescription products in the U.S.: Natesto®, the first
and only FDA-approved nasal formulation of testosterone for men
with hypogonadism (low testosterone, or "Low T") and ProstaScint®
(capromab pendetide), the only FDA-approved imaging agent specific
to prostate specific membrane antigen (PSMA) for prostate cancer
detection and staging. Additionally, Aytu is developing MiOXSYS®, a
novel, rapid semen analysis system with the potential to become a
standard of care for the diagnosis and management of male
infertility caused by oxidative stress. MiOXSYS® is
commercialized outside the U.S. where it is a CE Marked, Health
Canada cleared, Australian TGA approved product, and Aytu is
planning U.S.-based clinical trials in pursuit of 510k medical
device clearance by the FDA. Aytu's strategy is to continue
building its portfolio of revenue-generating products, leveraging
its focused commercial team and expertise to build leading brands
within growing markets. For more information visit aytubio.com.
Aytu also now owns wholly-owned subsidiary Aytu Women's Health
(formerly Nuelle, Inc.), a personal health and wellness company
focused on women's sexual wellbeing and intimacy. Aytu Women's
Health markets Fiera, a personal care device for women that is
scientifically proven to enhance physical arousal and sexual
desire. Fiera is a consumer device and is not intended to treat,
mitigate, or cure any disease or medical condition. For more
information about the Fiera personal care device visit
fiera.com.
Forward Looking Statement
This press release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, or
the Exchange Act. All statements other than statements of
historical facts contained in this presentation, including
statements regarding our anticipated future clinical and regulatory
events, future financial position, business strategy and plans and
objectives of management for future operations, are forward-looking
statements. Forward looking statements are generally written in the
future tense and/or are preceded by words such as "may," "will,"
"should," "forecast," "could," "expect," "suggest," "believe,"
"estimate," "continue," "anticipate," "intend," "plan," or similar
words, or the negatives of such terms or other variations on such
terms or comparable terminology. These statements are just
predictions and are subject to risks and uncertainties that could
cause the actual events or results to differ materially. These
risks and uncertainties include, among others: risks relating to
gaining market acceptance of our products, the continued growth of
prescriptions and prescribers of Natesto, obtaining reimbursement
by third-party payors, the potential future commercialization of
our product candidates, the anticipated start dates, durations and
completion dates, as well as the potential future results, of our
ongoing and future clinical trials, the anticipated designs of our
future clinical trials, anticipated future regulatory submissions
and events, our anticipated future cash position and future events
under our current and potential future collaborations. We also
refer you to the risks described in "Risk Factors" in Part I, Item
1A of Aytu BioScience, Inc.'s Annual Report on Form 10-K and in the
other reports and documents we file with the Securities and
Exchange Commission from time to time.
Investor contact:
Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/aytu-bioscience-provides-update-on-the-continued-growth-of-natesto-in-the-us-300562107.html
SOURCE Aytu BioScience, Inc.